should submit a copy of their oral testimony in advance to
cfsac@hhs.gov, prior to the close of business on Wednesday, October
26, 2011. If you wish to remain anonymous, please notify the CFSAC
support team staff upon submission of your materials to cfsac@hhs.gov.
If you do not submit your written testimony by the close of business
Wednesday, October 26, 2011, you may bring a copy to the meeting and
present it to a CFSAC support team staff member. Your testimony will
be included in a notebook available for viewing by the public on a
table at the back of the meeting room.
Individuals who do not provide public comment at the meeting, but who
wish to have printed material distributed to CFSAC members for review
should submit, at a minimum, one copy of the material to the
Designated Federal Officer at cfsac@hhs.gov prior to close of business
on Wednesday, October 26, 2011. Submitted documents should be limited
to five typewritten pages. If you wish to remain anonymous, please
notify the CFSAC support team staff upon submitting your materials to
cfsac@hhs.gov.
All testimony and printed material submitted for the meeting are part
of the official meeting record and will be uploaded to the CFSAC Web
site; this material will be made available for public inspection.
Testimony and materials submitted should not include any sensitive
personal information, such as a person=92s social security number; date
of birth; driver=92s license number, State identification number or
foreign country equivalent; passport number; financial account number;
or credit or debit card number. Sensitive health information, such as
medical records or other personal identifiable health information, or
any non-public corporate or trade association information, such as
trade secrets or other proprietary information also should be excluded
from any materials submitted.
CFSAC was established on September 5, 2002. The Committee shall advise
and make recommendations to the Secretary, through the Assistant
Secretary for Health, on a broad range of topics including
The current state of knowledge and research and the relevant gaps in
knowledge and research about the epidemiology, etiologies, biomarkers
and risk factors relating to CFS, and identifying potential
opportunities in these areas;
impact and implications of current and proposed diagnosis and
treatment methods for CFS; development and implementation of programs
to inform the public, health care professionals, and the biomedical
academic and research communities about CFS advances; and partnering
to improve the quality of life of CFS patients.
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
